Monthly Horizon Scanning Report – January 2023
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Estradiol spray for the treatment of menopausal symptoms
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Prescribing Update Newsletter – January 2022
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition covers the use of steroid medication warning cards for children and young people, National Detect, Protect and Perfect programme and choice of DOACs, Primary Care Discussions: Focus on Diabetes, and SPS: New guides for providing medicines advice and/or prescribing in pregnancy. It also continues a series of spotlight articles on one of the types of RDTC stakeholder level report; this month looks at the new Monthly Formulary Amendments report.
Monthly Formulary Amendments – January 2022
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, RMOC Guidance, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
It includes a suggested formulary position for APCs/Formulary Committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Monthly Horizon Scanning Report – January 2022
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies
This information is produced for use by NHS healthcare professionals.
Cost Comparison Charts
Overview
The charts included within this report are organised by BNF classification (legacy) and show comparative costs at the NHS basic price1,2 (as of January 2023) for selected agents. Except where indicated otherwise, each chart shows the cost of 1 year3 of treatment at a commonly prescribed daily dose (shown in brackets). The doses given are not intended to imply therapeutic equivalence and for some BNF sub-classifications, such as angiotensin converting enzyme inhibitors (ACE inhibitors), the doses may vary according to indication. Additionally, in some therapeutic areas, for instance antibacterial drugs, the duration of treatment may differ from that shown. Primarily, this report focuses on costs related to prescribing in adults. There are however a few exceptions where products specifically for use in children are represented, such as in the emollient and Infant formulas sections. Additional notes to highlight any relevant cost related information are also added where appropriate, to improve the clarity of the information presented.
Rationale for inclusion: the cost comparison charts (CCCs) aim to represent the diversity of products available; including the least expensive, most prescribed, higher cost products being prescribed and products with additional features. The products included are furthermore considered in the context of national and local guidance and stakeholder formulary decisions. It is not possible to represent all pharmaceuticals within these charts.
Stakeholders (under password protection) can access the current version of the CCCs via our website in three formats: PDF, Word and Excel. The Excel version incorporates a more detailed comparison of contraceptives and allows charts to be split by BNF subsections in some instances.
References
1. NHS Business Services Authority (NHS BSA). Drug tariff.
2. NHS BSA. Dictionary of medicines and devices (dM+d).
3. 1 year in this instance is equal to 364 days (rather than 365) standardising 1 month as equal to 28 days.
Time Period
January 2023
Frequency
Quarterly
Drug Tariff Monitor
Overview
The purpose of this report is to present the predicted cost impact of category A, M and C drug tariff PartVIIIA price changes on primary care spending. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at SICBL and ICB level.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
January 2023 (Drug Tariff), November 2022 (ePACT2 Prescribing data)
Prescribing Update Newsletter – January 2021
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
Monthly Horizon Scanning Report – Jan 2021
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Impact of Priadel Price Change on CCG Prescribing Budgets
This bulletin aims to raise awareness of the NHS price increase for Priadel® (lithium carbonate) tablets as of November 2020 and the resulting cost impact to primary care. While discussions between the DHSC and the manufacturer of Priadel have prevented its discontinuation from the UK market at this stage, the renegotiated price in November 2020 has seen the cost more than double from December 2020.
There are three versions of this publication; please select the appropriate version for your region below.